Discovery and molecular mechanism of potent neutralizing antibody from humanized mice with respiratory syncytial virus. [PDF]
Zhang Z +11 more
europepmc +1 more source
Is Palivizumabe a Protective Factor for the Development of Asthma in Children? A Systematic Review With Metanalysis. [PDF]
Manini MB +4 more
europepmc +1 more source
The implications for health of European Union enlargement. [PDF]
McKee, Martin, Nolte, Ellen
core +1 more source
Informe técnico palivizumab inyectable
En base a la revisión de la información científica respecto al medicamento Palivizumab 50mg inyectable, el Equipo Técnico acuerda no incluirlo en la Lista Complementaria de medicamentos al Petitorio Nacional Único de Medicamentos Esenciales (PNUME) debido a que no reduce la mortalidad y no es costo efectivo.
openaire +1 more source
Improvement in Palivizumab Administration in Severely Immunocompromised Children: A Single-institution Quality Improvement Initiative. [PDF]
Hijano DR +12 more
europepmc +1 more source
Prevalence of Resistance-Associated Mutations in RSV F Protein Against Monoclonal Antibodies Prior to Widespread Implementation: Findings From a Prospective German Pediatric Cohort. [PDF]
Wetzke M +9 more
europepmc +1 more source
RSV vaccine development: advances and fusion protein-focused strategies. [PDF]
Xu W, Katte RH, Lu M.
europepmc +1 more source
Recommendation for use of a long-acting monoclonal antibody to prevent respiratory syncytial virus infection in infants and young children. [PDF]
Choi SH +15 more
europepmc +1 more source
Respiratory Syncytial Virus Infection in Immunocompromised Patients Revisited [PDF]
Hirsch, Hans H., Khanna, Nina
core
Complementary Strategy of Maternal Immunization with RSVpreF Vaccine and Monoclonal Antibodies for the Prevention of Respiratory Syncytial Virus Among Italian Infants: A Cost-Effectiveness Assessment. [PDF]
Polistena B +5 more
europepmc +1 more source

